曲唑酮治疗精神分裂症伴发焦虑症状31例

摘要目的探讨曲唑酮对伴发焦虑症状的精神分裂症患者的疗效。方法伴发焦虑症状的精神分裂症患者61例，随机分为治疗组31例，对照组30例。两组原有抗精神病药物治疗不变，治疗组加用曲唑酮25～100 mg•d－1，po。在治疗前及治疗后第4，8周末均用汉密尔顿焦虑量表（HAMA）评定焦虑的严重程度，用简明精神病评定量表（BPRS）评定精神分裂症的病情程度，用个人和社会功能量表（PSP）评定其社会功能。结果治疗组和对照组在第8周末的HAMA总分分别为（15.32±4.13），（17.97±3.54）分；躯体性焦虑因子分分别为（7.32±2.86），（9.10±2.55）分（P＜0.05）；BPRS总分分别为（32.45±3.33），（34.77±4.63）分（P＜0.05）；焦虑忧郁因子分分别为（8.48±0.81），（10.90±2.03）分（P＜0.01）；PSP评分分别为（70.55±5.21），（66.17±6.07）分（P＜0.01）。结论曲唑酮治疗伴发焦虑症状精神分裂症患者，在改善焦虑症状的同时也有利于病情的改善及社会功能的恢复。

Efficacy of Trazodone in Treatment of Schizophrenia with Anxious Symptoms

Objective To study the therapeutic effect of trazodone on anxious symptoms,disease condition and social function of schizophrenic patients.Methods Sixty-one schizophrenic patients with anxiety symptoms were selected and randomly divided into two groups: treated group(n=31) and control group(n=30).Both groups were treated with the same antipsychotic drugs,while the treated group was added with trazodone.Severity of anxious symptoms of each patient was assessed with Hamilton Anxiety Scale(HAMA),schizophrenic severity with Brief Psychiatric Rating Scale(BPRS) and social functions with Personal and Social Performance scale(PSP) before the treatment and at the ends of the 4th and 8th weeks after the treatment.Results At the end of the 8th week after the treatment,HAMA total scores of treated group and control group were(15.32±4.13) and(17.97±3.54);somatic-anxiety factor scores were(7.32±2.86) and(9.10±2.55)(P<0.05);BPRS total scores were(32.45±3.33) and(34.77±4.63)(P<0.05);anxiety-depression factor scores were(8.48±0.81) and(10.90±2.03)(P<0.01);PSP scores were(70.55±5.21) and(66.17±6.07)(P<0.01).Conclusion Trazodone can alleviate anxious symptoms and disease condition,and improve social function of schizophrenic patients with anxiety symptoms.